Microba Life Sciences Limited (FWB:F3Y) Filings

Microba Life Sciences Limited

Filings

FilingDateTypeFiled with
BCAL Position on GSS-MAP MergerNov 18, 2026Acquisition or disposalASX
MAP: Proposed Merger with GSS not proceedingNov 17, 2026Acquisition or disposalASX
GSS: End of Proposed Merger with Microba Life SciencesNov 17, 2026Acquisition or disposalASX
Suspension from QuotationNov 16, 2026Trading halt or suspensionASX
TOV: GSS - Panel Receives ApplicationNov 13, 2026Other filingsASX
Trading Halt RequestNov 13, 2026Trading halt or suspensionASX
Trading HaltNov 13, 2026Trading halt or suspensionASX
Pause in TradingNov 12, 2026Trading halt or suspensionASX
Cleansing NoticeOct 28, 2026FinancingASX
Application for quotation of securities - MAPOct 27, 2026FinancingASX
Letter to Shareholders, Notice of AGM & Proxy FormOct 27, 2026Meeting noticeASX
Final Director's Interest Notice - Ian FrazerOct 26, 2026Ownership change noticeASX
Final Director's Interest Notice - Gene TysonOct 26, 2026Ownership change noticeASX
Notification of cessation of securities - MAPOct 22, 2026FinancingASX
Update on Commercial Terms for Proposed Merger with MAPOct 20, 2026Acquisition or disposalASX
Proposed issue of securities - MAPOct 19, 2026FinancingASX
Proposed issue of securities - MAPOct 19, 2026FinancingASX
Q1 FY27 Quarterly Activities Report & Appendix 4COct 19, 2026Quarterly reportASX
Q1 FY27 Quarterly Activities Report & Appendix 4COct 19, 2026Quarterly reportASX
Microba secures $2m placement and increases cost reductionsOct 19, 2026FinancingASX
Microba secures $2m placement and increases cost reductionsOct 19, 2026FinancingASX
Date of AGM and closing date for Director NominationsOct 13, 2026Meeting noticeASX
Notification of cessation of securities - MAPOct 13, 2026FinancingASX
Microba launches GI Navigator in Australia and the UKOct 6, 2026Operations updateASX
Change in substantial holdingSep 30, 2026Ownership change noticeASX
Appointment of Interim Chief Executive OfficerSep 24, 2026Management or board changeASX
GSS and MAP agree to Commercial Terms for MergerSep 21, 2026Acquisition or disposalASX
2026 Annual Report & Appendix 4EAug 30, 2026Annual reportASX
2026 Appendix 4GAug 30, 2026Other filingsASX
2026 Corporate Governance StatementAug 30, 2026Other filingsASX
Genetic Signatures and Microba in Merger DiscussionsAug 25, 2026Acquisition or disposalASX
Change of Director's Interest Notice - Pasquale RombolaJul 31, 2026Ownership change noticeASX
Change of Director's Interest Notice - Prof Ian FrazerJul 31, 2026Ownership change noticeASX
Cleansing NoticeJul 29, 2026FinancingASX
Notification regarding unquoted securities - MAPJul 28, 2026Other filingsASX
Notification regarding unquoted securities - MAPJul 28, 2026Other filingsASX
Application for quotation of securities - MAPJul 28, 2026FinancingASX
Notification regarding unquoted securities - MAPJul 28, 2026Other filingsASX
Application for quotation of securities - MAPJul 28, 2026FinancingASX
Completion of Share Purchase PlanJul 27, 2026FinancingASX
Q4 FY26 Quarterly Investor Presentation & WebinarJul 15, 2026Quarterly reportASX
Investor presentation - path to cashflow breakevenJun 11, 2026Other filingsASX
Pause in TradingJun 2, 2026Trading halt or suspensionASX
Q3 FY26 Quarterly Investor Presentation & WebinarApr 29, 2026Other filingsASX
Appendix 4D & FY26 Interim ReportFeb 25, 2026Interim reportASX
Q2 FY26 Quarterly Investor Presentation & WebinarJan 28, 2026Other filingsASX
Q2 FY26 Quarterly Activities Report & Appendix 4CJan 28, 2026Quarterly reportASX
Microba receives $3 million R&D Tax Incentive RefundDec 2, 2025ResultsASX
Q1 FY26 Quarterly Investor Presentation & WebinarOct 27, 2025Quarterly reportASX
Q1 FY26 Quarterly Activities Report & Appendix 4COct 27, 2025Quarterly reportASX
2025 Annual Report & Appendix 4EAug 26, 2025Annual reportASX
Q4 FY25 Quarterly Investor Presentation & WebinarJul 21, 2025Quarterly reportASX
Q4 FY25 Quarterly Activities Report & Appendix 4CJul 21, 2025Quarterly reportASX
Disclosure Document - ProspectusJun 27, 2025Offer documentASX
Reinstatement to QuotationJun 23, 2025Trading halt or suspensionASX
Strategic Investment & Equity Raise PresentationJun 23, 2025Other filingsASX
Microba secures $14.5 million to drive clinical adoptionJun 23, 2025FinancingASX
Suspension from QuotationJun 23, 2025Trading halt or suspensionASX
Trading HaltJun 18, 2025Trading halt or suspensionASX
MetaPanel Pathogen Study Delivers Breakthrough ResultsMay 20, 2025ResultsASX
Landmark GI Study Results from over 4,600 patientsMay 13, 2025ResultsASX
Q3 FY25 Quarterly Investor Presentation & WebinarApr 29, 2025Quarterly reportASX
Q3 FY25 Quarterly Activities Report & Appendix 4CApr 29, 2025Quarterly reportASX
Appendix 4D & FY25 Interim ReportFeb 25, 2025Interim reportASX
Q2 FY25 Quarterly Investor Presentation & WebinarJan 28, 2025Quarterly reportASX
Q2 FY25 Quarterly Activities Report & Appendix 4CJan 28, 2025Quarterly reportASX
Trading UpdateNov 28, 2024Operations updateASX
Microba receives $6 million R&D Tax Incentive RefundNov 17, 2024Other filingsASX
Q1 FY25 Quarterly Activities Report & Appendix 4COct 28, 2024Quarterly reportASX
Q1 FY25 Quarterly Investor PresentationOct 28, 2024Other filingsASX
2024 Annual Report & Appendix 4EAug 28, 2024Annual reportASX
Q4 FY24 Quarterly Investor Presentation & WebinarJul 24, 2024Quarterly reportASX
Q4 FY24 Quarterly Activities Report & Appendix 4CJul 24, 2024Quarterly reportASX
Completion of Autoimmune Program with Ginkgo BioworksJun 27, 2024Operations updateASX
Q3 FY24 Quarterly Investor PresentationApr 22, 2024Quarterly reportASX
Q3 FY24 Quarterly Activities Report & Appendix 4CApr 22, 2024Quarterly reportASX
Microba receives $6.08 million R&D Tax Incentive RefundApr 10, 2024ResultsASX
MetaPanel Launch Investor PresentationMar 12, 2024Other filingsASX
MetaPanel Diagnostic Test Launched with Sonic HealthcareMar 12, 2024Other filingsASX
Appendix 4D & FY24 Interim ReportFeb 27, 2024Interim reportASX
Q2 FY24 Quarterly Investor PresentationJan 29, 2024Quarterly reportASX
Q2 FY24 Quarterly Activities Report & Appendix 4CJan 29, 2024Quarterly reportASX
Successful IBD Phase I Clinical TrialDec 6, 2023Other filingsASX
Research Agreement Executed with IFF for Allergy ProgramDec 3, 2023Other filingsASX
Autoimmune Stage 1 Screening Complete with Gingko BioworksNov 27, 2023Operations updateASX
Results of Retail Entitlement OfferNov 19, 2023ResultsASX
Fully Underwritten A$20 million Entitlement OfferOct 22, 2023FinancingASX
Invivo Clinical Acquisition and Capital Raising PresentationOct 18, 2023FinancingASX
Microba to acquire UK microbiome leader Invivo ClinicalOct 18, 2023Acquisition or disposalASX
Q1 FY24 Quarterly Activities Report & Appendix 4COct 18, 2023Quarterly reportASX
Appendix 4E & Annual ReportAug 29, 2023Annual reportASX
Q4 FY23 Quarterly Investor PresentationJul 26, 2023Other filingsASX
Q4 FY23 Quarterly Activities Report & Appendix 4CJul 26, 2023Quarterly reportASX
First Distribution Agreement Executed with Sonic HealthcareJul 4, 2023Other filingsASX
Microba Commences Phase I Clinical Trial for IBD TherapeuticJun 27, 2023Other filingsASX
MRFF Grant Awarded to QUT, In Collaboration With MicrobaJun 27, 2023Other filingsASX
Microba receives two AusIndustry Advanced Overseas FindingsJun 14, 2023Other filingsASX
Q3 FY23 Quarterly Investor PresentationApr 19, 2023Other filingsASX
Q3 FY23 Quarterly Activities Report & Appendix 4CApr 19, 2023Quarterly reportASX
SYNLAB Contracts Signed in Poland, Hungary, Romania, CroatiaApr 12, 2023Other filingsASX
Microba Receives Ethics Approval for Phase 1 Clinical TrialMar 29, 2023Other filingsASX
SYNLAB Agreements Signed in Turkiye and Czech RepublicMar 1, 2023Other filingsASX
Microba Launches Next Generation Healthcare TestingFeb 27, 2023Other filingsASX
H1 FY23 Interim ReportFeb 22, 2023Interim reportASX
US Distribution Agreement Signed with Luminary HealthFeb 6, 2023Other filingsASX
Positive first animal data for Cancer ProgramJan 31, 2023Other filingsASX
Q2 FY23 Quarterly Activities Report & Appendix 4CJan 29, 2023Quarterly reportASX
SYNLAB Agreements Signed in Italy and PortugalDec 7, 2022Other filingsASX
Sonic Investment & Partnership Investor PresentationNov 28, 2022Other filingsASX
Sonic Acquires 19.9% Microba Stake and Enters PartnershipNov 28, 2022Acquisition or disposalASX
Microba receives $2.62m R&D Tax Incentive refundOct 31, 2022Other filingsASX
Q1 FY23 Quarterly Activities Report & Appendix 4COct 26, 2022Quarterly reportASX
Microba, SYNLAB Extend & Expand DistributionOct 19, 2022Other filingsASX
Therapeutic Program AdvancementAug 30, 2022Other filingsASX
Investor Presentation - FY22 Update Annual ResultsAug 29, 2022Other filingsASX
Q4 FY22 Quarterly Activities Report & Appendix 4CJul 19, 2022Quarterly reportASX
G42 Healthcare Partnership Commences OperationJun 27, 2022Other filingsASX
Microba & Ginkgo Commence Therapeutics ProgramJun 7, 2022Other filingsASX
Partnership signed with nib-backed Midnight HealthMay 25, 2022Other filingsASX
Microba Accelerates Cancer ProgramMay 5, 2022Other filingsASX